Quintiles And Eisai Collaborate To Develop Cancer Compounds

Moving beyond the traditional contract research organization model, Quintiles will collaborate with Eisai to perform 11 proof-of-concept trials on six oncology compounds in a deal announced Oct. 30

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip